---
title: "RBC Capital Sticks to Their Buy Rating for uniQure (QURE)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294352283.md"
description: "RBC Capital analyst Luca Issi reiterated a Buy rating on uniQure (QURE) with a $65 price target, noting the stock closed at $40.07. This follows a recent Buy from Barclays' Eliana Merle, while Goldman Sachs maintains a Hold rating. Issi covers the healthcare sector and has a 39.45% success rate on recommendations."
datetime: "2026-07-30T11:07:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294352283.md)
  - [en](https://longbridge.com/en/news/294352283.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294352283.md)
generator: "portal-rs"
---

# RBC Capital Sticks to Their Buy Rating for uniQure (QURE)

In a report released yesterday, Luca Issi from RBC Capital reiterated a Buy rating on uniQure, with a price target of $65.00. The company’s shares closed yesterday at $40.07.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Issi covers the Healthcare sector, focusing on stocks such as Argenx Se, Alnylam Pharma, and uniQure. According to TipRanks, Issi has an average return of -1.4% and a 39.45% success rate on recommended stocks. 

In addition to RBC Capital, uniQure also received a Buy from Barclays’s Eliana Merle in a report issued today. However, on July 20, Goldman Sachs maintained a Hold rating on uniQure (NASDAQ: QURE).

### Related Stocks

- [QURE.US](https://longbridge.com/en/quote/QURE.US.md)

## Related News & Research

- [Walid Abi-Saab Sells 30,000 Shares of uniQure (NASDAQ:QURE) Stock](https://longbridge.com/en/news/291590037.md)
- [Positive Report for uniQure (QURE) from Barclays](https://longbridge.com/en/news/290583750.md)
- [Wedbush Keeps Their Buy Rating on IDEAYA Biosciences (IDYA)](https://longbridge.com/en/news/296510282.md)
- [BMO Capital Sticks to Their Buy Rating for Merck & Company (MRK)](https://longbridge.com/en/news/296482637.md)
- [Deutsche Bank  Keeps Their Buy Rating on DocMorris (DOCM)](https://longbridge.com/en/news/296474032.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**